chloroquine has been researched along with Obesity in 12 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
Excerpt | Relevance | Reference |
---|---|---|
"The phytochemical sulforaphane (SFN) has been studied for its potential anti-obesity effect, but neither its molecular targets nor its interaction with the antimalarial drug chloroquine (CQ) has been fully delineated." | 8.12 | Chloroquine modulates the sulforaphane anti-obesity mechanisms in a high-fat diet model: Role of JAK-2/ STAT-3/ SOCS-3 pathway. ( Abdallah, DM; Ali, MA; Ashmawy, AI; El-Abhar, HS, 2022) |
"Cardiotoxicity is a well-known side effect of chloroquine." | 3.91 | Revisiting the Cardiotoxic Effect of Chloroquine. ( Blignaut, M; Dhanabalan, K; Espach, Y; Huisamen, B; van Vuuren, M, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (8.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (8.33) | 29.6817 |
2010's | 4 (33.33) | 24.3611 |
2020's | 6 (50.00) | 2.80 |
Authors | Studies |
---|---|
Ashmawy, AI | 1 |
El-Abhar, HS | 1 |
Abdallah, DM | 1 |
Ali, MA | 1 |
Chee, YJ | 1 |
Tan, SK | 1 |
Yeoh, E | 1 |
Watanabe, LM | 1 |
Pires, IF | 1 |
Noronha, NY | 1 |
Pinhel, MAS | 1 |
Nonino, CB | 1 |
Nachega, JB | 1 |
Ishoso, DK | 1 |
Otokoye, JO | 1 |
Hermans, MP | 1 |
Machekano, RN | 1 |
Sam-Agudu, NA | 1 |
Bongo-Pasi Nswe, C | 1 |
Mbala-Kingebeni, P | 1 |
Madinga, JN | 1 |
Mukendi, S | 1 |
KoliƩ, MC | 1 |
Nkwembe, EN | 1 |
Mbuyi, GM | 1 |
Nsio, JM | 1 |
Mukeba Tshialala, D | 1 |
Tshiasuma Pipo, M | 1 |
Ahuka-Mundeke, S | 1 |
Muyembe-Tamfum, JJ | 1 |
Mofenson, L | 1 |
Smith, G | 1 |
Mills, EJ | 1 |
Mellors, JW | 1 |
Zumla, A | 1 |
Mavungu Landu, DJ | 1 |
Kayembe, JM | 1 |
Huang, C | 1 |
Hsu, HJ | 1 |
Wang, ME | 1 |
Hsu, MC | 1 |
Wu, LS | 1 |
Jong, DS | 1 |
Jiang, YF | 1 |
Chiu, CH | 1 |
Zhang, S | 1 |
Zhu, H | 1 |
Ye, H | 1 |
Hu, Y | 1 |
Zheng, N | 1 |
Huang, Z | 1 |
Xiong, Z | 1 |
Fu, L | 1 |
Cai, T | 1 |
Gabriel, TL | 2 |
Mirzaian, M | 1 |
Hooibrink, B | 2 |
Ottenhoff, R | 1 |
van Roomen, C | 2 |
Aerts, JMFG | 1 |
van Eijk, M | 2 |
Blignaut, M | 1 |
Espach, Y | 1 |
van Vuuren, M | 1 |
Dhanabalan, K | 1 |
Huisamen, B | 1 |
Tol, MJ | 1 |
Ottenhof, R | 1 |
Aten, J | 1 |
Claessen, N | 1 |
de Weijer, B | 1 |
Serlie, MJ | 1 |
Argmann, C | 1 |
van Elsenburg, L | 1 |
Aerts, JM | 1 |
Mu, Y | 1 |
Yan, WJ | 1 |
Yin, TL | 1 |
Zhang, Y | 1 |
Li, J | 1 |
Yang, J | 1 |
Osman, MM | 1 |
Khalil, A | 1 |
Ahmed, MH | 1 |
Fischer, P | 1 |
Nostitz, HJ | 1 |
1 review available for chloroquine and Obesity
Article | Year |
---|---|
Dissecting the interaction between COVID-19 and diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Blood Glucose; Chloroquine; Comorbidity; COVID- | 2020 |
11 other studies available for chloroquine and Obesity
Article | Year |
---|---|
Chloroquine modulates the sulforaphane anti-obesity mechanisms in a high-fat diet model: Role of JAK-2/ STAT-3/ SOCS-3 pathway.
Topics: Animals; Chloroquine; Diet, High-Fat; Isothiocyanates; Janus Kinase 2; Liver; Obesity; Random Alloca | 2022 |
The influence of bitter-taste receptor (TAS2R) expression in pharmacological response to Chloroquine in obese patients with COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Obe | 2020 |
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo.
Topics: Adolescent; Adult; Asymptomatic Diseases; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatme | 2020 |
Fatty acids suppress the steroidogenesis of the MA-10 mouse Leydig cell line by downregulating CYP11A1 and inhibiting late-stage autophagy.
Topics: Animals; Autophagy; Chloroquine; Cholesterol Side-Chain Cleavage Enzyme; Endocrine Cells; Fatty Acid | 2021 |
Risk factors for prolonged virus shedding of respiratory tract and fecal in adults with severe acute respiratory syndrome coronavirus-2 infection.
Topics: Adult; Animals; Antiviral Agents; CD4 Lymphocyte Count; Chloroquine; COVID-19; Feces; Female; Humans | 2021 |
Induction of Sphk1 activity in obese adipose tissue macrophages promotes survival.
Topics: Adipose Tissue; Animals; CD11b Antigen; Cell Survival; Cells, Cultured; Chloroquine; Cluster Analysi | 2017 |
Revisiting the Cardiotoxic Effect of Chloroquine.
Topics: Animals; Antimalarials; Cardiotoxicity; Cell Survival; Chloroquine; Dose-Response Relationship, Drug | 2019 |
Lysosomal stress in obese adipose tissue macrophages contributes to MITF-dependent Gpnmb induction.
Topics: Adipose Tissue; Adult; Animals; Cell Nucleus; Cells, Cultured; Chloroquine; Female; Humans; Interleu | 2014 |
Diet-induced obesity impairs spermatogenesis: a potential role for autophagy.
Topics: Adenine; Animals; Apoptosis; Autophagy; Cells, Cultured; Chloroquine; Diet, High-Fat; Humans; Infert | 2017 |
Chloroquine-induced nitric oxide: new treatment for an emerging epidemic of obesity-related glomerulopathy.
Topics: Antirheumatic Agents; Chloroquine; Glomerulonephritis; Humans; Nitric Oxide; Obesity | 2006 |
[Progressive chronic polyarthritis and active body mass].
Topics: Adipose Tissue; Adult; Arthritis, Rheumatoid; Body Weight; Chloroquine; Creatinine; Humans; Methods; | 1971 |